Meiji Announces Board Approval to Cancel Loan Facility to Subsidiary Alvogen Korea Holdings Ltd.
Key facts
- Meiji Announces Board Approval to Cancel Loan Facility to Subsidiary Alvogen Korea Holdings Ltd.
- Meiji Chemical Pharmaceutical Co., Ltd. has announced that its board of directors has approved the cancellation of a USD 15 million loan facility previously allocated to its subsidiary, Alvogen Korea Holdings Ltd., citing operational adjustments.
- Source: PR Times
- Date: June 27, 2026
Direct answer
Meiji Chemical Pharmaceutical Co., Ltd. has announced that its board of directors has approved the cancellation of a USD 15 million loan facility previously allocated to its subsidiary, Alvogen Korea Holdings Ltd., citing operational adjustments.
- Citation
- Meiji Announces Board Approval to Cancel Loan Facility to Subsidiary Alvogen Korea Holdings Ltd. (June 27, 2026), PR Times
- Source
- PR Times
- Date
- June 27, 2026
Meiji Chemical Pharmaceutical Co., Ltd. has announced that its board of directors has approved the cancellation of a USD 15 million loan facility previously allocated to its subsidiary, Alvogen Korea Holdings Ltd., citing operational adjustments.
📋 Article Processing Timeline
- 📰 Published: June 27, 2026 at 09:00
- 🔍 Collected: June 27, 2026 at 23:58 (14h 58m after Published)
- 🤖 AI Analyzed: June 28, 2026 at 00:01 (2 min after Collected)
Release Date: June 27, 2026
Statement Date: June 26, 2026
Statement Time: 19:44:33
Company Code: 1795
Company Name: Meiji
Subject: Announcement of Board Resolution to Cancel Loan Facility to Subsidiary Alvogen Korea Holdings Ltd.
Applicable Clause: Item 51
Factual Date: June 26, 2026
Details:
1. Factual Date: June 26, 2026
2. Company Name: Meiji Chemical Pharmaceutical Co., Ltd.
3. Relationship with Company (Please enter 'Company' or 'Subsidiary'): Company
4. Cross-shareholding Ratio: 100%
5. Reason for Occurrence: In alignment with current operational realities, the company has decided to cancel the USD 15 million loan facility previously allocated to Alvogen Korea Holdings Ltd.
6. Response Measures: Not applicable
7. Other Matters to be Disclosed: This significant information simultaneously meets the criteria under Article 7, Paragraph 9, Item 9 of the Enforcement Rules of the Securities and Exchange Act, concerning matters that significantly affect shareholder rights or securities prices. No additional disclosures are required.
Statement Date: June 26, 2026
Statement Time: 19:44:33
Company Code: 1795
Company Name: Meiji
Subject: Announcement of Board Resolution to Cancel Loan Facility to Subsidiary Alvogen Korea Holdings Ltd.
Applicable Clause: Item 51
Factual Date: June 26, 2026
Details:
1. Factual Date: June 26, 2026
2. Company Name: Meiji Chemical Pharmaceutical Co., Ltd.
3. Relationship with Company (Please enter 'Company' or 'Subsidiary'): Company
4. Cross-shareholding Ratio: 100%
5. Reason for Occurrence: In alignment with current operational realities, the company has decided to cancel the USD 15 million loan facility previously allocated to Alvogen Korea Holdings Ltd.
6. Response Measures: Not applicable
7. Other Matters to be Disclosed: This significant information simultaneously meets the criteria under Article 7, Paragraph 9, Item 9 of the Enforcement Rules of the Securities and Exchange Act, concerning matters that significantly affect shareholder rights or securities prices. No additional disclosures are required.
FAQ
What kind of company is Meiji?
A Taiwan-based chemical pharmaceutical company specializing in the development, manufacturing, and distribution of generic drugs.
What is the impact of this decision?
Affects capital strategy in Taiwan and Korea operations, with potential implications for investor relations.
What will happen to Alvogen Korea Holdings Ltd.?
It is expected to continue operations through internal funds or alternative financing, though growth may slow.